Excerpted from AVAC Report: HIV Prevention on the Line, this update details attempts to test vaccine strategy which showed promise in the RV144 trial.
Intervention Update: What’s Next for AIDS Vaccines and the P5 Partnership?
Turning Targets into Impact
This graphic, which appears in the AVAC Report 2014/15, lists and describes key attributes that ensure a target into impact.
Mind the Gap
This graphic, presented in the AVAC Report 2014/15: HIV Prevention on the Line, shows all the components of a comprehensive response to end the epidemic.
Targets that Require Work: PrEP and Combination Prevention
Targets are urgently needed for daily oral PrEP and combination prevention. This graphic, from AVAC Report 2014/15: HIV Prevention on the Line, proposes goals and shows what’s in place and what is missing today.
Past Success, Present Gaps: VMMC targets, 2011 and today
VMMC (VMMC) is a highly effective HIV prevention strategy that has benefited from ambitious target setting that ticked all the boxes—investment, political will and evidence. This graphic is from AVAC Report 2014/15: HIV Prevention on the Line.
What to Expect for PrEP in Africa in 2015
Appearing in the AVAC Report 2014/15: HIV Prevention on the Line, this graphic shows ongoing and completed PrEP trials in Africa.
An Advocate’s Guide to Tracking the P5 Development Tracks
This graphic, shown in the AVAC Report 2014/15, shows the P5 development and research track trials.
AVAC Report 2014/15: Prevention on the Line [Executive Summary]
This executive summary, excerpted from AVAC Report 2014/15, puts the current discussion about global targets for ending AIDS in context. What makes a good target? What targets have worked in the past—and why? What is the state of HIV prevention targets and plans today?
Essential Actions for HIV Prevention Research Rollout 2014/15
This updated version of AVAC’s 3D graphic shows priorities across the research-to-rollout spectrum. The graphic appears in AVAC Report 2014/15: Prevention on the Line.
FY2015 US Global AIDS Budget Plan: The Human Impact
The US government’s efforts to fight the global AIDS pandemic through both the US President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund to Fight AIDS, Tuberculosis and Malaria have been transformative in the global AIDS response. To maintain the current total level of US global HIV/AIDS funding in Fiscal Year 2015, the US House of Representatives has proposed restoring US$300 million in PEPFAR funding. As illustrated in this infographic, amfAR has estimated the potential human impact of US$300 million to expand lifesaving HIV prevention, Treatment U=U and care services.